Boutique advisory focused on EU GMP pharma and chemical manufacturing. Working directly with owners and plant leadership teams to stabilise, optimise and prepare sites for growth, inspections or transactions.

Key focus areas:

- Pharmaceutical technology and engineering: development, optimisation and scale-up of manufacturing processes.

- Identifying and removing production bottlenecks, improving throughput and OEE on existing assets.

- Enhancing Quality Management Systems (QMS) in line with EU GMP expectations.

- Selection, assessment and implementation of production and auxiliary equipment for new and existing lines.

- Hands-on support to mid-size EU GMP sites in CEE/Balkans that need practical, plant-level expertise rather than generic consulting.

- Led the recovery of suspended sterile manufacturing by forming a crisis team and agreeing on weekly progress reporting with the regulator (Ravimiamet). Restored the manufacturing license within ~2.5 months, preventing ~€1M in monthly downtime losses, retaining key customers, and avoiding the need to relocate production to the Netherlands.

- Restructured the organization by strengthening the leadership team (including a Technical Manager, Head of HR, QP and other critical roles) and establishing a dedicated QP/QA function. This ensured stable operations without constant hands-on “manual control” and increased investor confidence in a €50–60M turnover business with a workforce of ~180 employees.

- Increased sterile output by 25% (from ~1.2M to 1.5M+ units per month) through improved planning and bottleneck removal, generating an additional €200–250K in monthly revenue (~€2.4–3.0M annually) without a proportional increase in fixed costs - by improving utilization of existing equipment and capacity rather than adding CAPEX.

- Restored licenses for aerosol and intramammary products, updating the MIA, expanding the active product portfolio, improving diversification and investment attractiveness.

- Led preparation for and the successful completion of a critical inspection by the national regulator (Ravimiamet) within an EU GMP framework, building a transparent regulator communication process and materially reducing regulatory risk under high-pressure conditions.

- Led a 2,400 m2 greenfield facility build-out to EU GMP/GACP standards for medical cannabis products with a €7M CAPEX budget. Delivered €1.7M (~20%) savings through design/scope optimisation and contractor selection. Ramped operations with a 15–20-person team and materially improved the project’s investment efficiency and payback profile.

- Built and EU GMP-certified a full manufacturing chain (flowers, extracts, API/FDF), including a QC laboratory (AMV/QCM) and CTD dossier preparation. Export model to Australia, UK and Germany.

- Managed €850K+ OPEX. Ensured day-to-day cost control and a stable operating run-rate during ramp-up and transition to routine operations.

- Delivered commercial entry into export markets by aligning customer requirements and adapting products/documentation. Established sales in both spot and off-take models. Occasionally accepted minimal initial margins to enter priority markets.